{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:23:34Z","timestamp":1791289414993,"version":"4.3.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"10","content-domain":{"domain":["cell.com","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.tips.2013.08.001","type":"journal-article","created":{"date-parts":[[2013,9,13]],"date-time":"2013-09-13T17:15:46Z","timestamp":1379092546000},"page":"560-570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists"],"prefix":"10.1016","volume":"34","author":[{"given":"Guy A.","family":"Higgins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Sellers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2013.08.001_bib0005","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0091-3057(01)00745-6","article-title":"The medical benefit of 5-HT research","volume":"71","author":"Jones","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.tips.2013.08.001_bib0010","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1517\/13543776.2010.518956","article-title":"5-HT2C receptor modulators: a patent survey","volume":"20","author":"Lee","year":"2010","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.tips.2013.08.001_bib0015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0079-6468(07)00006-9","article-title":"5-HT2C ligands: recent progress","volume":"46","author":"Monck","year":"2008","journal-title":"Prog. Med. Chem."},{"key":"10.1016\/j.tips.2013.08.001_bib0020","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrn3105","article-title":"Common cellular and molecular mechanisms in obesity and drug addiction","volume":"12","author":"Kenny","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.tips.2013.08.001_bib0025","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nn1452","article-title":"How can drug addiction help us understand obesity?","volume":"8","author":"Volkow","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.tips.2013.08.001_bib0030","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1176\/appi.ajp.164.5.708","article-title":"Issues for DSM-V: should obesity be included as a brain disorder?","volume":"164","author":"Volkow","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.tips.2013.08.001_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2009.03.011","article-title":"Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy","volume":"123","author":"Henningfield","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tips.2013.08.001_bib0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrd3914","article-title":"Smoking cessation drugs market","volume":"12","author":"Syed","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2013.08.001_bib0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1113\/jphysiol.2008.164152","article-title":"Pharmacological targeting of the serotonergic system for the treatment of obesity","volume":"587","author":"Garfield","year":"2009","journal-title":"J. Physiol."},{"key":"10.1016\/j.tips.2013.08.001_bib0050","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0079-6123(08)00919-9","article-title":"Dopamine\/serotonin releasers as medications for stimulant addictions","volume":"172","author":"Rothman","year":"2008","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.tips.2013.08.001_bib0055","series-title":"Handbook of Behavioural Neurobiology of Serotonin","first-page":"507","article-title":"The role of serotonin in drug addiction","author":"Muller","year":"2010"},{"issue":"Suppl. 1","key":"10.1016\/j.tips.2013.08.001_bib0060","first-page":"S18","article-title":"Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine","volume":"22","author":"Heal","year":"1998","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.tips.2013.08.001_bib0065","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2125.2009.03549.x","article-title":"Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders","volume":"68","author":"Heal","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tips.2013.08.001_bib0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pbb.2010.07.020","article-title":"New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?","volume":"97","author":"Kennett","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.tips.2013.08.001_bib0075","first-page":"CD000031","article-title":"Antidepressants for smoking cessation","volume":"1","author":"Hughes","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2013.08.001_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ADM.0b013e3181ce38e7","article-title":"The treatment of obesity and its co-occurrence with substance use disorders","volume":"4","author":"VanBuskirk","year":"2010","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.tips.2013.08.001_bib0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0014-2999(02)01751-X","article-title":"Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine","volume":"445","author":"Tao","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tips.2013.08.001_bib0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnint.2013.00025","article-title":"Serotonin modulation of cortical neurons and networks","volume":"7","author":"Celada","year":"2013","journal-title":"Front. Integr. Neurosci."},{"key":"10.1016\/j.tips.2013.08.001_bib0095","first-page":"157","article-title":"International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)","volume":"46","author":"Hoyer","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.tips.2013.08.001_bib0100","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0091-3057(01)00746-8","article-title":"Molecular, pharmacological and functional diversity of 5-HT receptors","volume":"71","author":"Hoyer","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.tips.2013.08.001_bib0105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/387303a0","article-title":"Regulation of serotonin-2C receptor G-protein coupling by RNA editing","volume":"387","author":"Burns","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.tips.2013.08.001_bib0110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pharmthera.2008.03.012","article-title":"RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function","volume":"119","author":"Werry","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tips.2013.08.001_bib0115","first-page":"913","article-title":"5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential","volume":"286","author":"Martin","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2013.08.001_bib0120","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1021\/jm970424c","article-title":"6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist","volume":"40","author":"Bromidge","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2013.08.001_bib0125","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/374542a0","article-title":"Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors","volume":"374","author":"Tecott","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.tips.2013.08.001_bib0130","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00213-010-2106-2","article-title":"Reversal of sibutramine-induced anorexia with a selective 5-HT2C receptor antagonist","volume":"214","author":"Higgs","year":"2011","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.tips.2013.08.001_bib0135","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s002130050952","article-title":"Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice","volume":"143","author":"Vickers","year":"1999","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.tips.2013.08.001_bib0140","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0028-3908(01)00063-6","article-title":"Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors","volume":"41","author":"Vickers","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0145","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nn1455","article-title":"Anatomy and regulation of the central melanocortin system","volume":"8","author":"Cone","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.tips.2013.08.001_bib0150","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1126\/science.1072327","article-title":"Activation of central melanocortin pathways by fenfluramine","volume":"297","author":"Heisler","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.tips.2013.08.001_bib0155","first-page":"1183","article-title":"Studies to investigate the role of 5-HT2C receptors on cocaine- and food-maintained behavior","volume":"295","author":"Grottick","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2013.08.001_bib0160","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00213-012-2919-2","article-title":"Evaluation of chemically diverse 5-HT2C receptor agonists on behaviours motivated by food and nicotine and on side effect profiles","volume":"226","author":"Higgins","year":"2013","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.tips.2013.08.001_bib0165","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1111\/j.1460-9568.2007.05567.x","article-title":"5-HT2C receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice","volume":"25","author":"Somerville","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.tips.2013.08.001_bib0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.yfrne.2009.10.003","article-title":"Appetite and reward","volume":"31","author":"Fulton","year":"2010","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.tips.2013.08.001_bib0175","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.tins.2007.03.003","article-title":"Regulation of firing of dopaminergic neurons and control of goal-directed behaviors","volume":"30","author":"Grace","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.tips.2013.08.001_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2013.04.030","article-title":"The use of the reinstatement model to study relapse to palatable food seeking during dieting","author":"Calu","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0185","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.conb.2011.09.004","article-title":"Metabolic and hedonic drives in the neural control of appetite: who is the boss?","volume":"21","author":"Berthoud","year":"2011","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.tips.2013.08.001_bib0190","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pharmthera.2006.08.004","article-title":"Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission","volume":"113","author":"Alex","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tips.2013.08.001_bib0195","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0006-8993(00)02246-0","article-title":"Biochemical and electrophysiological evidence that Ro 60-0175 inhibits mesolimbic dopaminergic function through serotonin2C receptors","volume":"865","author":"Di Matteo","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.tips.2013.08.001_bib0200","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/(SICI)1098-2396(20000601)36:3<205::AID-SYN5>3.0.CO;2-D","article-title":"Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat","volume":"36","author":"Gobert","year":"2000","journal-title":"Synapse"},{"key":"10.1016\/j.tips.2013.08.001_bib0205","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0028-3908(99)00047-7","article-title":"SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system","volume":"38","author":"Di Matteo","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0210","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0091-3057(01)00705-5","article-title":"Role of serotonin2C receptors in the control of brain dopaminergic function","volume":"71","author":"Di Matteo","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.tips.2013.08.001_bib0215","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.npp.1301509","article-title":"The 5-HT2C receptor agonist Ro60-0175 reduces cocaine self-administration and reinstatement induced by the stressor yohimbine, and contextual cues","volume":"33","author":"Fletcher","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00213-007-0916-7","article-title":"Stimulation of serotonin2C receptors influences cocaine-seeking behavior in response to drug-associated stimuli in rats","volume":"196","author":"Burbassi","year":"2008","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.tips.2013.08.001_bib0225","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.neuropharm.2011.04.034","article-title":"Selective serotonin 5-HT2C receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs sucrose-associated cues","volume":"61","author":"Cunningham","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0230","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/FBP.0b013e3282f1c94b","article-title":"Stimulation of 5-HT2C receptors attenuates cue and cocaine-primed reinstatement of cocaine-seeking behavior in rats","volume":"18","author":"Neisewander","year":"2007","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.tips.2013.08.001_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-006-0529-6","article-title":"Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure","volume":"189","author":"Epstein","year":"2006","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.tips.2013.08.001_bib0240","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/npp.2012.111","article-title":"Reduced forebrain serotonin transmission is causally involved in the development of compulsive cocaine seeking in rats","volume":"37","author":"Pelloux","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0245","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1124\/jpet.111.186981","article-title":"Effects of serotonin 2C receptor agonists on the behavioral and neurochemical effects of cocaine in squirrel monkeys","volume":"341","author":"Manvich","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2013.08.001_bib0250","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s002130100801","article-title":"Activation of 5-HT2C receptors reduces the locomotor and rewarding effects of nicotine","volume":"157","author":"Grottick","year":"2001","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.tips.2013.08.001_bib0255","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1471-4159.2004.02337.x","article-title":"Selective stimulation of serotonin2C receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration","volume":"89","author":"Di Matteo","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tips.2013.08.001_bib0260","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1124\/jpet.103.062208","article-title":"Stimulation of serotonin2C receptors blocks the hyperactivation of midbrain dopamine neurons induced by nicotine administration","volume":"309","author":"Pierucci","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2013.08.001_bib0265","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-007-0802-3","article-title":"The serotonin 2C receptor agonist Ro-60-0175 attenuates effects of nicotine in the five-choice serial reaction time task and in drug discrimination","volume":"193","author":"Quarta","year":"2007","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.tips.2013.08.001_bib0270","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejphar.2007.05.067","article-title":"Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats","volume":"571","author":"Zaniewska","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tips.2013.08.001_bib0275","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nm1349","article-title":"Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse","volume":"12","author":"Ji","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2013.08.001_bib0280","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00213-008-1404-4","article-title":"Effects of systemic and intra-nucleus accumbens 5-HT2C receptor compounds on ventral tegmental area self-stimulation thresholds in rats","volume":"203","author":"Hayes","year":"2009","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.tips.2013.08.001_bib0285","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbr.2008.08.034","article-title":"Differential effects of 5-HT2C receptor activation by WAY 161503 on nicotine-induced place conditioning and locomotor activity in rats","volume":"197","author":"Hayes","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.tips.2013.08.001_bib0290","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.neuropharm.2012.01.023","article-title":"Effects of the 5-HT2C receptor agonist Ro60-0175 and the 5-HT2A receptor antagonist M100907 on nicotine self-administration and reinstatement","volume":"62","author":"Fletcher","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0295","article-title":"Examination of the 5-HT2C receptor agonists lorcaserin and Ro 60-0175 against nicotine discrimination and dependence in the rat","author":"Higgins","year":"2011","journal-title":"Soc. Neurosci."},{"key":"10.1016\/j.tips.2013.08.001_bib0300","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.neuropharm.2010.02.006","article-title":"Effects of serotonin 5-HT2 receptor ligands on depression-like behavior during nicotine withdrawal","volume":"58","author":"Zaniewska","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0305","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.neuropharm.2011.02.025","article-title":"Impulsive action induced by amphetamine, cocaine and MK801 is reduced by 5-HT2C receptor stimulation and 5-HT2A receptor blockade","volume":"61","author":"Fletcher","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0310","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00213-007-0891-z","article-title":"Opposing effects of 5-HT2A and 5-HT2C receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test","volume":"195","author":"Fletcher","year":"2007","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.tips.2013.08.001_bib0315","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.bbr.2007.11.016","article-title":"The 5-HT2C receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test","volume":"188","author":"Navarra","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.tips.2013.08.001_bib0320","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00213-012-2929-0","article-title":"Impulsive action in the 5-choice serial reaction time test in 5-HT2C receptor null mutant mice","volume":"226","author":"Fletcher","year":"2013","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.tips.2013.08.001_bib0325","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1017\/S1461145711001635","article-title":"Impulsive action and impulsive choice are mediated by distinct neuropharmacological substrates in rat","volume":"15","author":"Paterson","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.tips.2013.08.001_bib0330","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/0269881105056639","article-title":"A comparison of multiple 5-HT receptors in two tasks measuring impulsivity","volume":"20","author":"Talpos","year":"2006","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.tips.2013.08.001_bib0335","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00213-003-1549-0","article-title":"The 5-HT2A receptor antagonist M100,907 attenuates motor and \u2018impulsive-type\u2019 behaviours produced by NMDA receptor antagonism","volume":"170","author":"Higgins","year":"2003","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.tips.2013.08.001_bib0340","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.tips.2008.01.002","article-title":"The neuropharmacology of impulsive behaviour","volume":"29","author":"Pattij","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2013.08.001_bib0345","first-page":"576","article-title":"Differential effects of the 5-HT2A receptor antagonist M100907 and the 5-HT2C receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding","volume":"27","author":"Fletcher","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0350","first-page":"357","article-title":"Antagonism of 5-hydroxytryptamine2A receptors attenuates the behavioral effects of cocaine in rats","volume":"297","author":"McMahon","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2013.08.001_bib0355","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1021\/cn300072u","article-title":"Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction","volume":"4","author":"Cunningham","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.tips.2013.08.001_bib0360","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/syn.21592","article-title":"5-HT2A receptor blockade and 5-HT2C receptor activation interact to reduce cocaine hyperlocomotion and Fos protein expression in the caudate-putamen","volume":"66","author":"Pockros","year":"2012","journal-title":"Synapse"},{"key":"10.1016\/j.tips.2013.08.001_bib0365","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/obr.12015","article-title":"Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs","volume":"14","author":"Chan","year":"2013","journal-title":"Obes. Rev."},{"key":"10.1016\/j.tips.2013.08.001_bib0370","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/clpt.2011.20","article-title":"Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users","volume":"89","author":"Shram","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tips.2013.08.001_bib0375","series-title":"Lorcaserin: Receptor Pharmacology and Selectivity. Arena Pharmaceuticals NDA 22-529 CR Resubmission","author":"Bourcier","year":"2012"},{"key":"10.1016\/j.tips.2013.08.001_bib0380","series-title":"Schedules of Controlled Substances: Placement of lorcaserin into Schedule IV","author":"Drug Enforcement Administration","year":"2013"},{"key":"10.1016\/j.tips.2013.08.001_bib0385","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/CIRCIMAGING.112.000128","article-title":"Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of three phase 3 clinical trials","volume":"6","author":"Weissman","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.tips.2013.08.001_bib0390","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMp1211277","article-title":"The FDA's assessment of two drugs for chronic weight management","volume":"367","author":"Colman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2013.08.001_bib0395","first-page":"S106","article-title":"A 6-week randomized, double-blind, placebo-controlled, comparator referenced, multicenter trial of Vabicaserin in subjects with acute exacerbation of schizophrenia","volume":"36","author":"Shen","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0400","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(11)61138-0","article-title":"Extent of illicit drug use and dependence, and their contribution to the global burden of disease","volume":"379","author":"Degenhardt","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2013.08.001_bib0405","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/npp.2011.84","article-title":"New medications for substance use disorders: challenges and opportunities","volume":"37","author":"Volkow","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0410","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/npp.2011.303","article-title":"The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control","volume":"37","author":"Higgins","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0415","first-page":"CD006219","article-title":"Interventions for preventing weight gain after smoking cessation","volume":"1","author":"Farley","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2013.08.001_bib0420","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1111\/j.1360-0443.2011.03493.x","article-title":"Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation","volume":"106","author":"Taylor","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.tips.2013.08.001_bib0425","first-page":"CD008286","article-title":"Combined pharmacotherapy and behavioural interventions for smoking cessation","volume":"10","author":"Stead","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2013.08.001_bib0430","first-page":"CD006103","article-title":"Nicotine receptor partial agonists for smoking cessation","volume":"4","author":"Cahill","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2013.08.001_bib0435","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3109\/07853890.2012.705016","article-title":"Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis","volume":"44","author":"Mills","year":"2012","journal-title":"Ann. Med."},{"key":"10.1016\/j.tips.2013.08.001_bib0440","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/clpt.2013.57","article-title":"Biomarkers for smoking cessation","volume":"93","author":"Bough","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tips.2013.08.001_bib0445","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.nbd.2010.04.004","article-title":"Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader-Willi syndrome","volume":"39","author":"Morabito","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2013.08.001_bib0450","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.nbd.2011.08.026","article-title":"Quantitative analysis of 5HT(2C) receptor RNA editing patterns in psychiatric disorders","volume":"45","author":"O\u2019Neil","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2013.08.001_bib0455","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.bjp.0702751","article-title":"Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells","volume":"128","author":"Porter","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2013.08.001_bib0460","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","article-title":"Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization","volume":"325","author":"Thomsen","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2013.08.001_bib0465","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.111.179572","article-title":"Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist","volume":"337","author":"Dunlop","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2013.08.001_bib0470","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neuropharm.2006.07.024","article-title":"CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity","volume":"52","author":"Siuciak","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0475","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0014-2999(01)00775-0","article-title":"Pharmacological characterisation of human 5-HT2 receptor subtypes","volume":"414","author":"Jerman","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tips.2013.08.001_bib0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104463","article-title":"Functional selectivity and classical concepts of quantitative pharmacology","volume":"320","author":"Urban","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2013.08.001_bib0485","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1124\/mol.64.1.78","article-title":"Positive allosteric modulator of the human 5-HT2C receptor","volume":"64","author":"Im","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2013.08.001_bib0490","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1021\/cn300020x","article-title":"Exploration of synthetic approaches and pharmacological evaluation of PNU-69176E and its stereoisomer as 5-HT2C receptor allosteric modulators","volume":"3","author":"Ding","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.tips.2013.08.001_bib0495","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2760","article-title":"Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders","volume":"8","author":"Conn","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2013.08.001_bib0500","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/mol.54.1.94","article-title":"Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus","volume":"54","author":"Berg","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2013.08.001_bib0505","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.neuropharm.2013.04.051","article-title":"Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications","volume":"72","author":"Morgan","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0510","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1523\/JNEUROSCI.2656-12.2013","article-title":"Peptide inhibitors disrupt the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog to allosterically modulate cellular signaling and behavior","volume":"33","author":"Anastasio","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2013.08.001_bib0515","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.neuroscience.2006.12.071","article-title":"Distribution of serotonin 5-HT2C receptors in the ventral tegmental area","volume":"146","author":"Bubar","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.tips.2013.08.001_bib0520","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.npp.1300319","article-title":"Injection of the 5-HT2C receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration","volume":"29","author":"Fletcher","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0525","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/sj.npp.1301414","article-title":"Differential regulation of the mesoaccumbens dopamine circuit by serotonin2C receptors in the ventral tegmental area and the nucleus accumbens: an in vivo microdialysis study with cocaine","volume":"33","author":"Navailles","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0530","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1471-4159.2002.00947.x","article-title":"Stimulation of 5-hydroxytryptamine (5-HT2C) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex","volume":"82","author":"Pozzi","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tips.2013.08.001_bib0535","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.neuroscience.2007.02.064","article-title":"Serotonin2C receptor localization in GABA neurons of the rat medial prefrontal cortex: implications for understanding the neurobiology of addiction","volume":"146","author":"Liu","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.tips.2013.08.001_bib0540","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/npp.2010.72","article-title":"Stimulation of medial prefrontal cortex serotonin 2C (5-HT2C) receptors attenuates cocaine-seeking behavior","volume":"35","author":"Pentkowski","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0545","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.pbb.2007.12.021","article-title":"Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry","volume":"90","author":"Dalley","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.tips.2013.08.001_bib0550","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/sj.bjp.0706935","article-title":"In vivo evidence that 5-HT2C receptors inhibit 5-HT neuronal activity via a GABAergic mechanism","volume":"149","author":"Boothman","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2013.08.001_bib0555","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/BF00172974","article-title":"Infusion of the 5-hydroxytryptamine agonists RU24969 and TFMPP into the paraventricular nucleus of the hypothalamus causes hypophagia","volume":"95","author":"Hutson","year":"1988","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.tips.2013.08.001_bib0560","doi-asserted-by":"crossref","first-page":"14630","DOI":"10.1523\/JNEUROSCI.5412-09.2010","article-title":"A serotonin and melanocortin circuit mediates D-fenfluramine anorexia","volume":"30","author":"Xu","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2013.08.001_bib0565","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pbb.2008.08.024","article-title":"Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats","volume":"91","author":"LeSage","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.tips.2013.08.001_bib0570","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00213-009-1739-5","article-title":"The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats","volume":"208","author":"O\u2019Connor","year":"2010","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.tips.2013.08.001_bib0575","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.neuropharm.2006.10.016","article-title":"Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid","volume":"52","author":"Rollema","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2013.08.001_bib0580","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/syn.20564","article-title":"Effect of varenicline on the acute and repeated locomotor responses to nicotine in rats","volume":"62","author":"Zaniewska","year":"2008","journal-title":"Synapse"},{"key":"10.1016\/j.tips.2013.08.001_bib0585","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1527-3458.2006.00178.x","article-title":"Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent","volume":"12","author":"Dwoskin","year":"2006","journal-title":"CNS Drug Rev."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614713001508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614713001508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T23:11:59Z","timestamp":1563923519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614713001508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":117,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0165614713001508"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2013.08.001","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2013.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}